Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)
September 11, 2026
A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced Cancer